Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a
company focused on developing, marketing and selling a variety of
men’s health and wellness products via a secure telemedicine
platform, including its uniquely formulated erectile dysfunction
(ED) drug branded “Mango,” is excited to announce that it has
engaged RedLime Solutions (“RedLime”), a global software
development and IT Consulting company as its software support and
development provider. Redlime has worked with major companies such
as Pepsi, Nokia, Pizza Hut, and AT&T having developed various
custom software solutions for them and their partners.
“Bringing the RedLime team into the equation is
a significant step toward engaging more customers, elevating the
MangoRx customer experience, reducing the friction around expanding
our product offerings, and laying a foundation for accelerating
growth through new strategies, features, and verticals,” remarked
Jacob Cohen. Mangoceuticals, Inc.’s Co-Founder and CEO. “This will
add eight top-tier dedicated software developers to our already
talented team, unleashing a new dimension to our growth outlook as
we shift into a new gear focused on commercialization of new,
innovative men’s health and wellness products and financial
performance.”
Management notes that the partnership with
RedLime is anticipated to:
- Add additional features to the
current customer journey and experience.
- Expand customer support
functionality including automation and other support features.
- Streamline the addition of new
products to the platform.
- Expand development and support in
anticipation of our affiliate marketing platform.
- Drive new development projects that
both enhance the current experience and for additional features and
verticals to support future revenue generating opportunities.
Tom Joardar, CEO of RedLime, commented, “We are
excited about the opportunity to work with MangoRx to help
facilitate the realization of its disruptive vision. The Company is
anticipating significant demand growth following recent strides in
marketing and visibility. It will be our job to help them handle
this increased demand by enhancing and augmenting the MangoRx
telemedicine platform on the back end to accommodate substantially
increased traffic and customer flow.”
MangoRx has recently commenced expanding its
marketing footprint, in part with its recent sponsorship
relationships with leading social media and podcast brands focused
on the men’s demographic, such as Barstool Sports, Only Stans,
Pillow Talk and No Jumper, as well as the nationwide launch of its
“Make America Hard Again” (www.MakeAmericaHardAgain.com)
campaign.
This expanded visibility comes in step with the
upcoming launch of the Company’s new sildenafil based Mango ED
product, which contains the active ingredient found in Viagra™.
This accompanies its original Mango Tadalafil flagship product,
which contains the active ingredient found in Cialis™. Both
products contain the Company’s proprietary and unique blend of
ingredients found in FDA approved products, including Oxytocin and
L-Arginine, and both are delivered via a rapidly dissolving
mango-flavored tablet that activates and dissolves orally for
faster results.
Cohen continued, “This partnership accomplishes
two of our main objectives right now: to establish a new technology
foundation capable of keeping up with significant demand growth,
and to set the stage for frictionless expansion into new verticals
focused on the growing men’s health and wellness marketplace. This
is a big piece of the puzzle coming into place and we look forward
to working with Tom and his very talented Redlime team.”
About Mango
Created using a special formulation featuring
the same active ingredient as in Cialis™ (Tadalafil), each part of
the Mango formulation plays a critical role in helping men achieve
optimum performance. We believe the key to our success lies in our
unique blend of ingredients, which are used in U.S. Food and Drug
Administration (“FDA”) approved drugs. Mango contains a combination
of Tadalafil, Oxytocin, and L-Arginine that have been traditionally
used to treat sexual dysfunction.
Mango is a prescription medication that must be
approved by a physician. After an individual has completed an
online tele-health visit, our network of medical providers will
review and approve a prescription if medically appropriate. Mango
is a rapidly dissolved tablet (RDT) that is absorbed orally. For
best results, we advise taking Mango at least 15 minutes before
engaging in sexual activity. Tadalafil, one of the main ingredients
in Mango, typically has effects that last up to 36 hours.
About Mangoceuticals
Mangoceuticals, Inc. is a company focused on
developing, marketing, and selling a variety of men's health and
wellness products and services via a secure telemedicine platform.
To date, the Company has identified men's wellness telemedicine
services and products as a growing sector and especially related to
the area of erectile dysfunction (ED). The Company has developed a
new brand of ED product under the brand name "Mango" (think: "Man,
Go!").
For more information, please visit
www.MangoRx.com.
Cautionary Note Regarding Forward-Looking
Statements
Certain statements made in this press release
contain forward-looking information within the meaning of
applicable securities laws, including within the meaning of the
Private Securities Litigation Reform Act of 1995 ("forward-looking
statements"). These forward-looking statements represent the
Company's current expectations or beliefs concerning future events
and can generally be identified using statements that include words
such as "estimate," "expects," "project," "believe," "anticipate,"
"intend," "plan," "foresee," "forecast," "likely," "will," "target"
or similar words or phrases. These forward-looking statements are
subject to risks, uncertainties and other factors, many of which
are outside of the Company's control which could cause actual
results to differ materially from the results expressed or implied
in the forward-looking statements, including, but not limited to;
our ability to obtain additional funding and generate revenues to
support our operations; risks associated with our ED product which
have not been, and will not be, approved by the U.S. Food and Drug
Administration ("FDA") and have not had the benefit of the FDA's
clinical trial protocol which seeks to prevent the possibility of
serious patient injury and death; risks that the FDA may determine
that the compounding of our planned products does not fall within
the exemption from the Federal Food, Drug, and Cosmetic Act ("FFDCA
Act") provided by Section 503A; risks associated with related party
relationships and agreements; the effect of data security breaches,
malicious code and/or hackers; competition and our ability to
create a well-known brand name; changes in consumer tastes and
preferences; material changes and/or terminations of our
relationships with key parties; significant product returns from
customers, product liability, recalls and litigation associated
with tainted products or products found to cause health issues; our
ability to innovate, expand our offerings and compete against
competitors which may have greater resources; our significant
reliance on related party transactions; the projected size of the
potential market for our technologies and products; risks related
to the fact that our Chairman and Chief Executive Officer, Jacob D.
Cohen and President, Jonathan Arango, combined have majority voting
control over the Company; risks related to the significant number
of shares in the public float, our share volume, the effect of
sales of a significant number of shares in the marketplace, and the
fact that the majority of our shareholders paid less for their
shares than the public offering price of our common stock in our
recent initial public offering; the fact that we have a significant
number of outstanding warrants to purchase shares of common stock
at $1.00 per share, the resale of which underlying shares have been
registered under the Securities Act of 1933, as amended; our
ability to build and maintain our brand; cybersecurity, information
systems and fraud risks and problems with our websites; changes in,
and our compliance with, rules and regulations affecting our
operations, sales, marketing and/or our products; shipping,
production or manufacturing delays; regulations we are required to
comply with in connection with our operations, manufacturing,
labeling and shipping; our dependency on third-parties to prescribe
and compound our ED product; our ability to establish or maintain
relations and/or relationships with third-parties; potential safety
risks associated with our Mango ED product, including the use of
ingredients, combination of such ingredients and the dosages
thereof; the effects of high inflation, increasing interest rates
and economic downturns, including potential recessions, as well as
macroeconomic, geopolitical, health and industry trends, pandemics,
acts of war (including the ongoing Ukraine/Russian conflict) and
other large-scale crises; our ability to protect intellectual
property rights; our ability to attract and retain key personnel to
manage our business effectively; our ability to maintain the
listing of our common stock on the Nasdaq Capital Market; overhang
which may reduce the value of our common stock; volatility in the
trading price of our common stock; and general consumer sentiment
and economic conditions that may affect levels of discretionary
customer purchases of the Company's products, including potential
recessions and global economic slowdowns. Although we believe that
our plans, intentions and expectations reflected in or suggested by
the forward-looking statements we make in this release are
reasonable, we provide no assurance that these plans, intentions or
expectations will be achieved. Consequently, you should not
consider any such list to be a complete set of all potential risks
and uncertainties.
More information on potential factors that could
affect the Company's financial results is included from time to
time in the "Cautionary Note Regarding Forward-Looking Statements,"
"Risk Factors" and "Management's Discussion and Analysis of
Financial Condition and Results of Operations" sections of the
Company's filings with the SEC, including the Company’s Quarterly
Report on Form 10-Q for the Quarter ended June 30, 2023. These
filings are available at www.sec.gov and at our website at
https://www.mangoceuticals.com/sec-filings. All subsequent written
and oral forward-looking statements attributable to the Company or
any person acting on behalf of the Company are expressly qualified
in their entirety by the cautionary statements referenced above.
Other unknown or unpredictable factors also could have material
adverse effects on the Company's future results. The
forward-looking statements included in this press release are made
only as of the date hereof. The Company cannot guarantee future
results, levels of activity, performance or achievements.
Accordingly, you should not place undue reliance on these
forward-looking statements. Finally, the Company undertakes no
obligation to update these statements after the date of this
release, except as required by law, and takes no obligation to
update or correct information prepared by third parties that are
not paid for by the Company. If we update one or more
forward-looking statements, no inference should be drawn that we
will make additional updates with respect to those or other
forward-looking statements.
Follow Mangoceuticals and MangoRx on social
media:https://www.instagram.com/mango.rx
https://twitter.com/Mangoceuticalshttps://www.facebook.com/MangoRxOfficial
Or just click here to see why Orange is the new
Blue:https://www.mangorx.com
FOR INVESTOR RELATIONSMangoceuticals Investor
RelationsEmail: investors@mangorx.com
MEDIA CONTACTPHOENIX MGMT Marketing &
Consultinginfo@phoenix-mediamarketing.comSOURCE:
Mangoceuticals Inc.
Mangoceuticals (NASDAQ:MGRX)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Mangoceuticals (NASDAQ:MGRX)
Historical Stock Chart
Von Jun 2023 bis Jun 2024